It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

dementia

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
Alzheimer's diagnosis revamp embraces rating scale similar to cancer

World / Science & Health Jul 17, 2023

Alzheimer's diagnosis revamp embraces rating scale similar to cancer

by Julie Steenhuysen

New guidelines would replace terminology such as mild, moderate and severe, instead using a numerical system related to disease progression.

Eisai appoints CEO’s son to lead global Alzheimer drug program

Business / Corporate Jul 11, 2023

Eisai appoints CEO’s son to lead global Alzheimer drug program

by Kanoko Matsuyama

Eisai's former global Alzheimer drug program officer, who led the push for U.S. approval of breakthrough medicine Leqembi, will retire at the end of the month.

Eisai Alzheimer's drug gets full U.S. approval, widening access to the therapy

World / Science & Health Jul 7, 2023

Eisai Alzheimer's drug gets full U.S. approval, widening access to the therapy

by Robert Langreth

The broader clearance from the Food and Drug Administration marks a milestone for treatment of the dementia that afflicts some 6 million Americans.

Expectations grow for Alzheimer's drug in Japan, but hurdles remain

National / Science & Health | FOCUS Jul 4, 2023

Expectations grow for Alzheimer's drug in Japan, but hurdles remain

by Tomoko Otake

Lecanemab could be approved in the country as early as fall, but more specialist doctors and a patient screening system would be needed for widespread use.

Can we cure dementia before it starts?

Commentary / World Jul 3, 2023

Can we cure dementia before it starts?

by F.D. Flam

Octogenarian and biologist Leroy Hood is trying to make the Elizabeth Holmes-ian dream of preventive medicine come true.

Dementia-related missing person cases doubled over past 10 years

National / Social Issues Jun 22, 2023

Dementia-related missing person cases doubled over past 10 years

by Yukana Inoue

A total of 18,709 people with dementia were reported missing in 2022, up 6.1% from the previous year.

New Eisai and Biogen Alzheimer drug faces hurdles in Europe

World / Science & Health Jun 19, 2023

New Eisai and Biogen Alzheimer drug faces hurdles in Europe

by Natalie Grover

Some doctors said its effect on the disease may not be clinically meaningful enough when weighed against the risk of brain swelling, its likely high price.

Parliament passes law aimed at supporting people with dementia

National / Science & Health Jun 15, 2023

Parliament passes law aimed at supporting people with dementia

by Kathleen Benoza

The health ministry expects the number of people with dementia in Japan to reach 7 million by 2025.

Obesity and Alzheimer's news makes Eli Lilly world’s most valuable drugmaker

Business Jun 1, 2023

Obesity and Alzheimer's news makes Eli Lilly world’s most valuable drugmaker

by Angel Adegbesan and Robert Langreth

An 8.5% gain in May for Eli Lilly lifted its shares to a record high, while displaced Johnson & Johnson slumped 5.3% during the month.

A breakthrough on Alzheimer's is closer than ever

Commentary / World May 17, 2023

A breakthrough on Alzheimer's is closer than ever

by Lisa Jarvis

Promising data could open the door to insurance coverage for expensive new Alzheimer's drugs, bringing them closer to patients.

Air pollution linked to increased dementia risk, Harvard researchers find

World / Science & Health Apr 6, 2023

Air pollution linked to increased dementia risk, Harvard researchers find

by Ilena Peng

The World Health Organization recommends that average annual PM2.5 levels be below 5 micrograms — but nearly the entire global population breathes air that exceeds those limits.

Asia turns to tech to help watch over a growing elderly population

Asia Pacific Jan 19, 2023

Asia turns to tech to help watch over a growing elderly population

by Rina Chandran

Smart home technologies such as cameras, robots, motion sensors and artificial intelligence-based speakers are being rolled out to help take care of loved ones.

VIEW OLDER ARTICLES

  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times